ライフサイエンスコーパス: haploidentical

1 re enrolled, 42 were HLA matched and 19 were haploidentical.

2 either mismatched unrelated (34%, P =.01) or haploidentical (21%, P =.002) patients.

3 ted: 37.4% [35.7-39.2] to 41.3% [39.5-43.1]; haploidentical: 34.5% [31.4-37.9] to 44.2% [42.1-46.3];

4 sibling donor, 8; matched family donor, 13; haploidentical, 4; and unrelated, 45.

5 ling, 70% vs 24%; unrelated, 61% vs 37%; and haploidentical, 88% vs 19%), attributable to less infect

6 kine release syndrome occurring from the MHC-haploidentical allo-HCT or interfering with PTCy-mediate

7 Although studies evaluating haploidentical allo-HSCT (haplo-HSCT) using posttranspla

8 secutive patients receiving a T cell-replete haploidentical allogeneic hematopoietic stem cell transp

9 ibilities (inc.) in the setting of T-replete haploidentical allogeneic hematopoietic stem cell transp

10 demonstrated in patients with AML undergoing haploidentical allogeneic HSCT and was suggested not to

11 constitution, particularly in MHC-mismatched haploidentical alloSCTs in which T cell-depleted allogra

12 eport 3-year survival exceeding 90% by using haploidentical alphabeta+CD3+/CD19+-depleted allogeneic

13 19 patients, we transplanted 17, 14 from HLA-haploidentical and 3 from HLA-matched related donors.

14 f hematopoietic cell engraftment in both the haploidentical and class II-disparate strain combination

15 on chromosome 6, encompassing LTV1, that was haploidentical and common to all affected individuals.

16 ith substantial progress among recipients of haploidentical and cord blood HSCT.

17 95% CI, 36-54) and 50% (95% CI, 47-53) after haploidentical and matched unrelated donor transplants (

18 In addition, peptide-treated mice in the haploidentical and MHC class II-mismatched strain combin

19 usion studies, including cells obtained from haploidentical and third-party donors, showed efficacy i

20 Haploidentical and umbilical cord blood donations may be

21 ng, matched unrelated, mismatched unrelated, haploidentical, and cord blood donors.

22 matched sibling, two matched unrelated, two haploidentical, and one single-antigen mismatched unrela

23 ng, matched unrelated, mismatched unrelated, haploidentical, and umbilical cord blood), and compared

24 Related HLA-haploidentical blood or marrow transplantation (BMT) wit

25 ances in nonmyeloablative (NMA), related HLA-haploidentical blood or marrow transplantation (haplo-BM

26 of secondary end points, including OS, favor haploidentical BM donors.

27 nors, one patient received a T-cell depleted haploidentical BM, and one patient received a non-T-cell

28 ated with 400 muCi (90)Y-DOTA-30F11, CY, and haploidentical BMT were cured and lived >200 days.

29 ultiple hematopoietic lineages 28 days after haploidentical BMT with 69.3 +/- 14.1%, 75.6 +/- 20.2%,

30 tively risk stratifies recipients of NMA HLA-haploidentical BMT with PTCy and also suggests that this

31 HLA-haploidentical BMT with PTCy using 400 cGy total body ir

32 efine outcomes of nonmyeloablative (NMA) HLA-haploidentical BMT with PTCy, 372 consecutive adult hema

33 RIT-mediated haploidentical BMT without TBI may increase treatment op

34 tion despite having received T cell-depleted haploidentical BMT.

35 an donor origin CD8(+) cells) 6 months after haploidentical BMT.

36 ined immune deficiency (SCID) patients given haploidentical bone marrow (BM), lesions in humoral immu

37 wer after UCB transplantations compared with haploidentical bone marrow and peripheral-blood transpla

38 lity after UCB transplantation compared with haploidentical bone marrow and peripheral-blood transpla

39 Compared with haploidentical bone marrow and peripheral-blood transpla

40 the 11 patients who could be evaluated, the haploidentical bone marrow cells engrafted.

41 ormal weight gain, the decision for SCT from haploidentical bone marrow or peripheral blood was made.

42 the hypothesis that nonmyeloablative-related haploidentical bone marrow transplant (BMT) with thiotep

43 es or bone marrow failure (BMF) who received haploidentical bone marrow transplantation (BMT) after e

44 Haploidentical bone marrow transplantation (BMT) with 30

45 espectively, compared with 58% and 46% after haploidentical bone marrow transplantation and 59% and 5

46 These results suggest that engraftment after haploidentical bone marrow transplantation for haemoglob

47 ine A (CSA) to promote chimerism in a murine haploidentical bone marrow transplantation model.

48 Haploidentical bone marrow transplantation using this ap

49 raft failure while maintaining the safety of haploidentical bone marrow transplantation with post-tra

50 ockade of B7/CD28 costimulation allows human haploidentical bone marrow transplantation without graft

51 renatally and successfully transplanted with haploidentical bone marrow.

52 months after kidney transplant from her HLA-haploidentical brother.

53 and GVHD-associated immune dysfunction in a haploidentical CBD2F1 (H2kxd) --> B6D2F1 (H2bxd) strain

54 greater challenge to the transplantation of haploidentical cells than thalassemia.

55 Lymphocytes from the peptide-treated haploidentical chimeric mice also displayed donor-specif

56 rs more frequently in patients receiving HLA-haploidentical compared with HLA-identical sibling trans

57 VHD (30% vs 53%, P < .0001) were lower after haploidentical compared with matched unrelated donor tra

58 , day 30 neutrophil recovery was lower after haploidentical compared with matched unrelated donor tra

59 ells were positively selected from a healthy haploidentical donor and infused intravenously twice, at

60 us-host disease prophylaxis, and 1.5 x 10(7) haploidentical donor bone marrow cells (day 0).

61 ers; however, characteristics of the optimal haploidentical donor have not been established.

62 vs 54%; P < .003), although in unconditioned haploidentical donor HCT, nonengraftment was a major pro

63 Purpose T-cell-replete HLA-haploidentical donor hematopoietic transplantation using

64 Furthermore, haploidentical donor memory CD8 T cells undergoing in vi

65 n support administration of large numbers of haploidentical donor T cells, resulting in rapid immune

66 ion (KT) after a previous HSCT from the same haploidentical donor typically received short-term immun

67 , respectively (P < .05 for those undergoing haploidentical donor v MRD or MUD transplantation).

68 0%), and the presence of an eligible related haploidentical donor.

69 CT from matched unrelated (66%; P < .05) and haploidentical donors (43%; P < .001).

70 n = 6), unrelated donors (UDs; n = 12), and haploidentical donors (HIDs; n = 7).

71 Alternative donor selection using haploidentical donors and posttransplantation cyclophosp

72 of alternative sources of stem cells such as haploidentical donors and umbilical cord cell blood.

73 Because many haploidentical donors can be identified in a family, the

74 We have now extended this to HLA-haploidentical donors in a pilot trial.

75 T-cell-replete grafts from haploidentical donors using post-transplantation cycloph

76 We compared outcomes of alloHCT using haploidentical donors with those of transplantation usin

77 ults, including use of older sibling donors, haploidentical donors, and emerging data for donor-assoc

78 ating nonmyeloablative conditioning, related haploidentical donors, and posttransplantation cyclophos

79 alternative donors, including cord blood and haploidentical donors, are highlighted, and we discuss r

80 rs or T-cell-depleted marrow stem cells from haploidentical donors, with whom there is a single haplo

81 sible and have limited the use of mismatched haploidentical donors.

82 lly matched related and unrelated donors and haploidentical donors.

83 ntemporaneously at a single center (53 using haploidentical donors; 117, MRDs; 101, MUDs) were compar

84 ent combined HCT/kidney transplantation from haploidentical donors; graft-versus-host disease (GVHD)

85 tation platform using related, including HLA-haploidentical, donors for patients with sickle cell dis

86 In the majority of patients, early haploidentical engraftment was replaced by durable engra

87 ulated, G-CSF-primed BM transplantation from haploidentical family donor provides very encouraging re

88 ted, G-CSF-primed BM transplantation from an haploidentical family donor.

89 ogenitor cell (HPC) transplantation from HLA-haploidentical family donors.

90 ies underwent blood HPC transplantation from haploidentical family donors.

91 Nonmyeloablative therapy using haploidentical family member donors is feasible because

92 rd blood (UCB) and CD34(+) stem cells from a haploidentical family member.

93 who were recipients of a PMRD allo-BMT from haploidentical family members following conditioning the

94 Transplant from haploidentical family members is indicated for patients

95 15 HLA genotypically identical siblings, 14 haploidentical family members, and 5 unrelated donors.

96 to either a tissue rejection response to the haploidentical fetus or from an undiagnosed infection.

97 ismatched unrelated grafts (45%, P =.01) and haploidentical grafts (42%, P =.001) compared with recip

98 Rapidly accessible CB and haploidentical grafts are suitable alternatives for pati

99 nipulated (without ex vivo T-cell depletion) haploidentical grafts combined with enhanced posttranspl

100 cs in 17 patients who received unmanipulated haploidentical grafts, containing high numbers of mature

101 nancy and those receiving mismatched related/haploidentical grafts, were 80% (+/-6%) and 77.7% (+/-6.

102 d unrelated grafts versus those who received haploidentical grafts.

103 28-day platelet recovery was delayed in the haploidentical group compared with the MSD group (63% v

104 The haploidentical group received graft-versus-host disease

105 post-transplantation cyclophosphamide-based haploidentical (HAPLO) allogeneic hematopoietic cell tra

106 sibling donor may have better outcomes than haploidentical (haplo) HSCT.

107 rug resistance was exclusively identified in haploidentical (haplo)-HSCT recipients receiving preempt

108 e graft sources, umbilical cord blood (UCB), haploidentical (haplo)-related donor, and mismatched unr

109 tical unfractionated and T cell-depleted HLA haploidentical, has been very successful in effecting im

110 eplacing total body irradiation (TBI) before haploidentical HCT in a murine model.

111 ld be applicable to major histocompatibility haploidentical HCT without excessive nonhematologic regi

112 Haploidentical hematopoietic cell transplantation (haplo

113 Related donor haploidentical hematopoietic cell transplantation (Haplo

114 reduced-intensity conditioning (RIC) for HLA-haploidentical hematopoietic cell transplantation (HCT)

115 r in a canine model of dog leukocyte antigen-haploidentical hematopoietic cell transplantation (HCT).

116 Nine additional animals received haploidentical hematopoietic cell transplantation follow

117 mplex (MHC)-defined miniature swine received haploidentical hematopoietic cell transplantation follow

118 oning with (211)At-CD45-B10 could be used in haploidentical hematopoietic cell transplantation though

119 All animals conditioned for haploidentical hematopoietic cell transplantation using

120 immune reconstitution in patients undergoing haploidentical hematopoietic stem cell transplant (haplo

121 tiviral and antitumor T cells, we infused 12 haploidentical hematopoietic stem cell transplant patien

122 -host disease (GVHD) has been observed after haploidentical hematopoietic stem cell transplantation (

123 tracked TSCM dynamics in patients undergoing haploidentical hematopoietic stem cell transplantation (

124 delta T lymphocytes up to 7 months after HLA-haploidentical hematopoietic stem cell transplantation (

125 ren with nonmalignant disorders received HLA-haploidentical hematopoietic stem cell transplantation (

126 Studies of haploidentical hematopoietic stem cell transplantation (

127 isease (GVHD) prophylaxis has revolutionized haploidentical hematopoietic stem cell transplantation (

128 onsecutive SCID-X1 patients having undergone haploidentical hematopoietic stem cell transplantation (

129 Haploidentical hematopoietic stem cell transplantation f

130 hese findings have important implications in haploidentical hematopoietic stem cell transplantation i

131 HLA-haploidentical hematopoietic stem cell transplantation i

132 HLA-haploidentical hematopoietic stem cell transplantation u

133 e studies have confirmed the efficacy of HLA-haploidentical hematopoietic stem cell transplantation w

134 ractionated HLA-identical or T cell-depleted haploidentical hematopoietic stem cell transplantation,

135 eta T-cell-depleted and CD19 B-cell-depleted haploidentical hematopoietic stem cells and a kidney fro

136 Recent analysis of haploidentical hematopoietic transplantations has shown

137 antiviral and antileukemia effects after HLA-haploidentical hematopoietic transplants depleted of alp

138 tigated the role of donor activating KIRs in haploidentical hematopoietic transplants for acute leuke

139 ed chimeras and recipients of MHC-matched or haploidentical HSCs with a shared MHC haplotype had T-de

140 nded donor NK cells infused before and after haploidentical HSCT for high-risk myeloid malignancies.

141 loped chronic kidney failure after receiving haploidentical HSCT from his father for the treatment of

142 developed a 2-step myeloablative approach to haploidentical HSCT in which 27 patients conditioned wit

143 However, the place of HLA-haploidentical HSCT remains less established.

144 restingly, this advantage of gene therapy vs haploidentical HSCT seems to be independent of the exist

145 lantation from the same donor after previous haploidentical HSCT with a corticosteroid taper alone.

146 igh doses of ex vivo-expanded NK cells after haploidentical HSCT without adverse effects, increased G

147 eic HSCT and might also not be restricted to haploidentical HSCT.

148 T cell-depleted and CD19(+) B cell-depleted haploidentical HSCT.

149 be an equal, if not superior, alternative to haploidentical HSCT.

150 ations could facilitate viral control in the haploidentical infant.

151 (HCT) regimen in dog leukocyte antigen (DLA)-haploidentical littermate recipients consisting of 450 c

152 in four control living unrelated and two HLA haploidentical living-related donor recipient pairs, whe

153 BMT from human leukocyte antigen-mismatched, haploidentical living-related donors after modified nonm

154 sm and engraftment can be established across haploidentical major histocompatibility complex barriers

155 from a related donor; 3 of the recipients of haploidentical marrow also received placental-blood tran

156 nd 2 of the 3 (67 percent) who received both haploidentical marrow and placental blood.

157 e engraftment of dog leukocyte antigen (DLA)-haploidentical marrow following a single dose of 9.2 Gy

158 schedule with the exception of recipients of haploidentical marrow grafts, who received antithymocyte

159 nt-specific CTLs enhanced engraftment of DLA-haploidentical marrow in 9 of 11 evaluable recipients (P

160 ting, only 4 of 11 control recipients of DLA-haploidentical marrow without added CTLs engrafted.

161 of HLA-identical marrow and 21 recipients of haploidentical marrow) between 2 percent and 100 percent

162 ow, 60 of the 77 (78 percent) who were given haploidentical marrow, and 2 of the 3 (67 percent) who r

163 mained abnormal in many of the recipients of haploidentical marrow.

164 fference; (2) (B6xDBA/2)F1 --> (B6xCBA)F1, a haploidentical MHC combination; and (3) B6.C-H2bm12 -->

165 transplantations; group 3 (n = 2) underwent haploidentical MHC-mismatched heart/kidney transplantati

166 i-tumor immune responses, the maintenance of haploidentical microchimerism may impart an allogeneic e

167 tibility antigen-mismatched as well as a MHC-haploidentical model of sclerodermatous cGVHD, pirfenido

168 transplantation (HSCT), the donor being her haploidentical mother.

169 iated major histocompatibility complex (MHC)-haploidentical murine bone marrow transplantation (BMT)

170 Using a clinically relevant haploidentical murine transplantation model, we showed t

171 Herein, we developed a T-cell-replete, MHC-haploidentical, murine HCT model (B6C3F1->B6D2F1) to tes

172 (n = 17), umbilical cord blood (n = 2), HLA-haploidentical (n = 1), or unknown (n = 3).

173 andomly assigned to undergo UCB (n = 186) or haploidentical (n = 182) transplant.

174 ted 917 adult lymphoma patients who received haploidentical (n = 185) or HLA-matched unrelated donor

175 ults with acute myeloid leukemia (AML) after haploidentical (n = 192) and 8/8 HLA-matched unrelated d

176 r genotypically DLA-identical (n = 9) or DLA-haploidentical (n = 9).

177 the safety, feasibility, and engraftment of haploidentical natural killer (NK) cell infusions after

178 Haploidentical natural killer (NK) cell infusions can in

179 n of AML were enrolled on the Pilot Study of Haploidentical Natural Killer Cell Transplantation for A

180 reated with major histocompatibility complex-haploidentical NK cell therapy for relapsed/refractory a

181 These findings suggest that haploidentical NK cells can persist and expand in vivo a

182 currently being tested clinically, including haploidentical NK cells, umbilical cord blood NK cells,

183 Because most patients have access to a haploidentical, one haplotype-mismatched donor, we have

184 but when a matched donor is not available, a haploidentical or mismatched unrelated donor (mMUD) can

185 We sought to evaluate the outcomes of haploidentical or mMUD HSCT after depleting GvHD-causing

186 (+)TCRalphabeta(+) and CD19(+) cell-depleted haploidentical or mMUD HSCT is a practical and viable al

187 ution in recipients with mismatches at half (haploidentical) or all major histocompatibility complex

188 Graft failure, 43% in haploidentical pairs, remains a major obstacle but may b

189 regulation was found in the remaining seven haploidentical pairs.

190 tested (7/7), and one half (9/18) of the HLA haploidentical pairs.

191 igen-identical or rigorously T cell-depleted haploidentical parental bone marrow transplantation (BMT

192 of the infants received T-cell-depleted, HLA-haploidentical parental marrow, and 12 received HLA-iden

193 from the most readily available source: the haploidentical, partially mismatched, related donor.

194 ed unrelated patients (26%, P =.014) than in haploidentical patients (42%).

195 Of the 57 haploidentical patients, there were 33 males and 24 fema

196 All nine DLA-haploidentical recipients of PBSC developed fatal hypera

197 Haploidentical recipients received calcineurin inhibitor

198 Haploidentical recipients received posttransplant cyclop

199 nt (CCR5(-/-)) donor cells to nonconditioned haploidentical recipients resulted in reduced donor cell

200 cGy TBI with postgrafting MMF/CSP in 44 DLA-haploidentical recipients using eight different regimens

201 ce to heart tissue from HSC donor strains in haploidentical recipients, showing potential application

202 genotypically identical sibling (GIS) or HLA-haploidentical related (HIR) donors between September 16

203 We previously found that non-myeloablative haploidentical related bone marrow transplantation with

204 ed double umbilical cord blood (dUCB) or HLA-haploidentical related donor bone marrow (Haplo-marrow)

205 in or non-Hodgkin lymphoma, the data support haploidentical related donor transplantation over UCB tr

206 onors, or mismatched unrelated donors versus haploidentical related donors (1.22, 0.65-2.27; p=0.98).

207 ents of transplants from non-sibling donors: haploidentical related donors (1.43, 0.81-2.50; p=0.21)

208 and in those who received a transplant from haploidentical related donors (5.30, 3.17-8.86; p<0.0001

209 Hematopoietic cell transplantation from HLA-haploidentical related donors is increasingly used to tr

210 a underwent bone-marrow transplantation from haploidentical related donors sharing at least one HLA A

211 ts had HLA-matched sibling donors, 137 [15%] haploidentical related donors, 111 [12%] matched unrelat

212 25 months (12-48) after transplantation from haploidentical related donors, 37 months (23-60) after t

213 s such as mismatched adult unrelated donors, haploidentical related donors, and umbilical cord blood

214 DRB1), including HLA-matched sibling donors, haploidentical related donors, matched unrelated donors,

215 with a low risk of complications, even with haploidentical related donors.

216 actors may help to optimize the selection of haploidentical related donors.

217 ukocyte antigen (HLA)- haplotype mismatched (haploidentical) related donors, suggesting that this pro

218 n leukocyte antigen (HLA)-mismatched, or HLA-haploidentical, related donor bone marrow transplantatio

219 Here, we test haploidentical, related-donor NK-cell infusions in a non

220 eveloped to facilitate selection of the best haploidentical-related donor by calculating disease-free

221 Haploidentical-related donor HSCT performed 2 months aft

222 ative using an URD, umbilical cord blood, or haploidentical-related donors; outcomes are either compa

223 stem cell transplantation (HSCT) from an HLA-haploidentical relative (haplo-HSCT) is a suitable optio

224 groups, including patients of any age with a haploidentical relative or HLA-mismatched unrelated dono

225 ors were HLA-identical siblings (n = 1,224); haploidentical relatives mismatched for one (n = 238) or

226 e of chronic rejection in living related one-haploidentical renal transplants in pediatric patients.

227 safely used to improve T-cell recovery after haploidentical SCT and may broaden the applicability of

228 lative preparative therapy with MEDI-507 and haploidentical SCT have led to the reliable induction of

229 se levels into recipients of T-cell-depleted haploidentical SCT.

230 l conditioning regimens, particularly in the haploidentical setting, justify further evaluation.

231 Similar to the haploidentical setting, use of PTCY is an effective anti

232 e and leads to tolerance toward the VCA in a haploidentical setting.

233 ), HLA-mismatched unrelated (n = 3), and HLA haploidentical sibling (n = 1).

234 , supported with purified CD34+ cells from a haploidentical sibling.

235 ery high-risk patients receiving combination haploidentical single-unit cord blood transplants, we ha

236 artially human leukocyte antigen-matched and haploidentical stem cell grafts (n = 13), without induci

237 lymphocyte reconstitution limits the use of haploidentical stem cell transplantation (SCT) because i

238 Poor immune reconstitution after haploidentical stem cell transplantation results in a hi

239 T cells from healthy donor and patient after haploidentical stem cell transplantation.

240 itiated a clinical trial of nonmyeloablative haploidentical stem-cell transplantation (SCT) using MED

241 te of graft rejection in patients undergoing haploidentical stem-cell transplantation.

242 inical success of cyclophosphamide (C)-based haploidentical stem-cell transplants indicates that this

243 hance immune reconstitution in recipients of haploidentical stem-cell transplants.

244 kedly reduces GvHD in a clinically relevant, haploidentical strain combination, while permitting anti

245 Transplantation of HLA-identical or haploidentical T cell-depleted allogeneic bone marrow (B

246 ients with increasing numbers of alloreplete haploidentical T cells expressing the inducible caspase

247 xt of CY tolerization, a high, fixed dose of haploidentical T cells was associated with encouraging o

248 donor, survival was best among recipients of haploidentical T-cell-depleted transplants in the absenc

249 Although haploidentical transplant modalities are based mainly on

250 Mismatched/haploidentical transplant provides an alternative approa

251 ment in the major histocompatibility complex-haploidentical transplant setting.

252 prophylaxis and management in the setting of haploidentical transplantation and in paediatric patient

253 t of NK cell alloreactivity if strategies of haploidentical transplantation are used: high stem cell

254 donors, suggesting that this procedure makes haploidentical transplantation available in all transpla

255 -cell population in the early days following haploidentical transplantation combined with pt-Cy and p

256 Recent advances have made haploidentical transplantation for leukemia feasible, bu

257 imulation with costimulatory blockade before haploidentical transplantation has demonstrated early pr

258 ncluded in the donor selection algorithm for haploidentical transplantation in children with acute ly

259 Today human leukocyte antigen-haploidentical transplantation is a feasible option for

260 The use of sirolimus in haploidentical transplantation is now being explored as

261 eukemia who received human leukocyte antigen-haploidentical transplantation of ex vivo T-cell-deplete

262 relapse in offspring with leukemia after HLA-haploidentical transplantation of maternal hematopoietic

263 The impact of newer approaches to haploidentical transplantation on Epstein-Barr virus (EB

264 Haploidentical transplantation performed using T-cell-re

265 In addition, patients who received a haploidentical transplantation received posttransplantat

266 Thus, CTLA4Ig-based haploidentical transplantation was associated with a low

267 ocytes in animal models, tomorrow's world of haploidentical transplantation will focus on new "design

268 suggest that reduced-intensity conditioning haploidentical transplantation with posttransplant cyclo

269 ts that survival for patients with AML after haploidentical transplantation with posttransplant cyclo

270 lantation outcomes in 71 patients undergoing haploidentical transplantation with posttransplantation

271 lusion, HLA factors influence the success of haploidentical transplantation with PTCy.

272 ted grafts substantially extended the use of haploidentical transplantation with results than even ri

273 Conclusion PB and BM grafts are suitable for haploidentical transplantation with the post-transplant

274 Severe GVHD developed after haploidentical transplantation without prophylaxis, char

275 Haploidentical transplantation would serve to extend the

276 For patients undergoing MRD, MUD, and haploidentical transplantation, 24-month cumulative inci

277 Of the 526 patients who received haploidentical transplantation, 68% received bone marrow

278 e 1990s saw what had been major drawbacks of haploidentical transplantation, ie, very strong host-ver

279 tion in Rag1 hypomorphic mice even following haploidentical transplantation, opening the way for the

280 rine and mycophenolate mofetil (MMF) and for haploidentical transplantation, posttransplant cyclophos

281 In T cell-depleted haploidentical transplantation, recent advances were mad

282 In HLA-haploidentical transplantation, we reported that donor-d

283 oring the GVL effect after HLA-A2-mismatched haploidentical transplantation.

284 man leukocyte antigen haplotype mismatched ("haploidentical") transplantation, its translation to cli

285 e emerging data for alternate donor (cord or haploidentical) transplantation in AA has provided addit

286 le variation was determined in 1,629 related haploidentical transplants to study the clinical signifi

287 1 CD3(+)TCR alphabeta/CD19 depleted parental haploidentical transplants were performed.

288 In contrast, of the nine HLA haploidentical transplants with bidirectional regulation

289 Of the nine HLA haploidentical transplants with unidirectional or no pre

290 he 110 enrolled participants who receive HLA-haploidentical transplants, daGOAT predicts intermediate

291 The study included a total of 28 haploidentical transplants, each with 2 to 5 HLA allele

292 Similarly, relative to haploidentical transplants, risk of chronic GVHD was hig

293 experienced primary graft failure had second haploidentical transplants.

294 well as URD with ATG (P = .01), relative to haploidentical transplants.

295 .21) or URD with ATG (P = .16), relative to haploidentical transplants.

296 ch) received cyclophosphamide, MEDI-507, and haploidentical unmanipulated bone marrow (n=8) or ex viv

297 Haploidentical, unmanipulated, G-CSF-primed bone marrow

298 variate analysis was 8%, 12%, and 17% in the haploidentical, URD without ATG, and URD with ATG groups

299 sion at 3 years was 36%, 28%, and 36% in the haploidentical, URD without ATG, and URD with ATG groups

300 We report the first therapeutic infusion of haploidentical virus-specific T lymphocytes (VSTs) to tr